Cost-Sharing Effects on Adherence and Persistence For Second-Generation Antipsychotics In Commercially Insured Patients

Teresa B. Gibson, PhD
Thompson Reuters (Healthcare) Inc.
Yonghua Jing, PhD
Bristol-Myers Squibb
Edward Kim, MD, MBA
Eisai Inc. (formerly Bristol-Myers Squibb)
Erin Bagalman, MSW
Thomson Reuters (Healthcare) Inc.
Sara Wang, PhD
Thomson Reuters (Healthcare) Inc.
Richard Whitehead
(formerly of Otsuka America Pharmaceutical Inc.)
Quynh-Van Tran, PharmD
Otsuka America Pharmaceutical Inc.
Jalpa A. Doshi, PhD
University of Pennsylvania School of Medicine


Purpose: To assess the relationship between patient cost-sharing (e.g., copayments or coinsurance) and adherence and persistence to second-generation (atypical) antipsychotic (SGA) medications.

Design and methodology: A retrospective, observational study of adults aged 18–64 years with schizophrenia or bipolar disorder (n=7,910) who initiated SGA medications with employer-sponsored insurance in the 2003–2006 MarketScan Commercial Claims and Encounters Database.

Adherence was defined as percent of days covered in each calendar quarter. Persistence was defined as days from initiation of SGA to the first 90-day gap in medication on-hand.

Generalized Estimating Equations were used to determine the effects of cost-sharing on adherence to SGA medications based on patient-quarter data.

A Cox proportional hazards model with patient cost-sharing as a time-varying covariate estimated the effects on persistence with SGA medication.

Principal findings: Higher cost-sharing was associated with a lower likelihood of adherence. When compared to plans with cost-sharing below $10, adherence rates were approximately 27% lower for patients in plans with SGA cost-sharing of $50 and above and about 10% lower for patients in plans with cost-sharing between $30 and $50. In both cases, the reduction in adherence was significant. Higher cost-sharing was also associated with a shorter time to discontinuation (HR: 1.028; 95% CI [1.006–1.051]).

Conclusion: High SGA cost-sharing appears to be a financial barrier to SGA medication compliance, especially when cost-sharing levels exceeded $30.

Our findings have implications for health plans, employers, and policymakers who have, or are, contemplating establishing cost-sharing tiers for SGA medications for commercially insured patients with serious mental illnesses.


A blueprint for high-volume, high-quality lung cancer screening that is detecting cancer earlier—and helping to save lives

Clinical Brief

Multiple Sclerosis: New Perspectives on the Patient Journey–2019 Update
Summary of an Actuarial Analysis and Report